Carbepenam Resistance Prevalence in North India: A Retrospective Analysis

Background: We investigated the clinical consequences of healthcare-associated bacteremia in light of rising antimicrobial resistance and limited therapy choices for carbapenem-resistant bacteremia. Methods: Between March 2020 and March 2022, a retrospective observational study of carbapenem-resistant Gram-negative bacteremia was conducted at a tertiary care hospital in North India. Results: Patients in our study spent an average of 11.76 days in the intensive care unit (ICU), with a mean time to bacteremia of 6.4 days following admission. Klebsiella pneumoniae was the most prevalent pathogen (44 percent). Patients receiving combination treatment had a reduced death rate (44.8%) than those receiving colistin monotherapy (66.6%) (P = 0.35). Conclusion: Carbapenem resistant bacteremia is a late-onset illness that affects patients who have been exposed to antibiotics in the ICU and has a 60 percent mortality rate after 30 days.